Literature DB >> 21556506

Induction of p-glycoprotein, glutathione-s-transferase-pi, catalase, C-fos and C-erbb1 in rodent cell-lines after exposure to Doxorubicin, ethanol and caffeine.

M Volm, T Efferth, P Grabner, E Pommerenke.   

Abstract

Murine NIH-3T3 cells were exposed to doxorubicin (DOX, 1 mu g/ml), ethanol (EtOH, 0.2%) and caffeine (CAFF, 200 mu g/ml) and analyzed for the induction of resistance proteins (P-glycoprotein, glutathione S-transferase-pi, catalase) and oncoproteins (c-EOS, c-ERBB1). P-glycoprotein (P-170), glutathione S-transferase-pi (GST-pi) and catalase (CAT) levels were found to be elevated after exposure of the cells to doxorubicin. In EtOH-treated cells the P-170 level was moderately increased (12 to 36 h after exposure), whereas the GST-pi and CAT levels were greatly increased (1 to 48 h). CAFF caused a moderate increase of P-170 (12 to 36 h) and of GST-pi (6 to 72 h). The accumulation of rhodamine 123 was reduced after the level of the resistance proteins had risen. After exposure to DOX, c-FOS was expressed moderately whereas c-ERBB1 was expressed strongly. Both oncoproteins showed a significant increase after exposure to EtOH. Only a moderate increase of c-FOS was seen after exposure to CAFF. Five out of seven additionally investigated rodent cell lines showed an increase in the expression of P-170, GST-pi and c-FOS after exposure to DOX, EtOH or CAFF.

Entities:  

Year:  1995        PMID: 21556506     DOI: 10.3892/ijo.6.1.87

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

Authors:  Alaa H Abuznait; Shawn G Patrick; Amal Kaddoumi
Journal:  J Pharm Pharm Sci       Date:  2011       Impact factor: 2.327

Review 2.  EGFR may couple moderate alcohol consumption to increased breast cancer risk.

Authors:  Christopher P Mill; Julia A Chester; David J Riese
Journal:  Breast Cancer (Dove Med Press)       Date:  2009-10-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.